4-乙氧基-N-(5-硝基噻唑-2-基)苯甲酰胺
| 中文名称 | 4-乙氧基-N-(5-硝基噻唑-2-基)苯甲酰胺 |
|---|---|
| 中文同义词 | 4-乙氧基-N-(5-硝基噻唑-2-基)苯甲酰胺;化合物MID-1;化合物MID-1,10 MM DMSO 溶液 |
| 英文名称 | Benzamide, 4-ethoxy-N-(5-nitro-2-thiazolyl) |
| 英文同义词 | Benzamide, 4-ethoxy-N-(5-nitro-2-thiazolyl);4-ethoxy-N-(5-nitrothiazol-2-yl)benzamide;ChemBridge5655896;MID-1,inhibit,Inhibitor,MG53,ubiquitination,Insulin Receptor,insulin,association,glucose,MID1,IRS-1,MID 1,degradation;4-ethoxy-N-(5-nitro-1,3-thiazol-2-yl)benzamide;MID-1, 10 mM in DMSO |
| CAS号 | 312608-54-1 |
| 分子式 | C12H11N3O4S |
| 分子量 | 293.3 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 312608-54-1.mol |
| 结构式 | ![]() |
4-乙氧基-N-(5-硝基噻唑-2-基)苯甲酰胺 性质
| 密度 | 1.442±0.06 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜:31.25 mg/mL(106.55 mM) |
| 酸度系数(pKa) | 6.62±0.50(Predicted) |
| 形态 | 固体 |
| 颜色 | 橙至红色 |
MID-1 (5 μM; 24 h) increases the IRS-1 expression level in skeletal muscle by disrupting the MG53-IRS-1 interaction.
MID-1 (10 μM; 12 h) reduces the luciferase activity in HEK 293 cell line expressing NLUC-IRS-1 and CLUC-C14A.
MID-1 (1-20 μM; 12 h) disrupts the MG53-IRS-1 interaction but not MG53-FAK interaction in HEK 293 cells.
MID-1 (0.1-10 μM; 4-24 h) abolishes MG53-induced IRS-1 ubiquitination and degradation in HEK 293 cells.
MID-1 (5-10 μM; 24 h) increases insulin signaling and insulin-elicited glucose uptake in C2C12 myotubes.
MID-1 (5-10 μM; 24 h) enhances skeletal myogenesis.
Western Blot Analysis
| Cell Line: | C2C12 myotubes |
| Concentration: | 5 μM |
| Incubation Time: | 24 h |
| Result: | Increased the IRS-1 protein level. |
MID-1 does not have good pharmacokinetics in vivo.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/09/15 | HY-115461 | 4-乙氧基-N-(5-硝基噻唑-2-基)苯甲酰胺 MID-1 | 312608-54-1 | 1 mg | 434元 |
| 2026/09/15 | HY-115461 | 4-乙氧基-N-(5-硝基噻唑-2-基)苯甲酰胺 MID-1 | 312608-54-1 | 5 mg | 998元 |
